{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:10:16Z","timestamp":1788801016141,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Emerg Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Substance-related emergency department (ED) visits increasingly present with agitation and behavioral instability rather than discrete toxidromes. Early decisions regarding escalation and disposition may be influenced by observable behavioral severity in addition to suspected substance category and initial pharmacologic regimen. We evaluated predictors of pharmacologic escalation and psychiatric admission among adults requiring psychoactive medication for substance-related behavioral disturbance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study was conducted in a tertiary ED between January 2024 and January 2025. Adult patients with clinician-judged substance-related presentations who received antipsychotics or benzodiazepines for immediate behavioral control were included. Agitation severity was assessed using the Overt Agitation Severity Scale (OASS) and categorized as mild (0), moderate (1), or severe (\u2265\u20092). The primary outcome was pharmacologic escalation, defined as the addition of a second antipsychotic or benzodiazepine. The secondary outcome was psychiatric admission. Predictors were evaluated using multivariable logistic regression. Model discrimination was assessed using bootstrap internal validation (1,000 resamples). An exploratory receiver operating characteristic (ROC) analysis was performed to evaluate the discriminative performance of OASS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ninety encounters were analyzed (median age 32 years; 86.7% male), of which 61.1% had severe agitation (OASS\u2009\u2265\u20092). Pharmacologic escalation occurred in 23.3% and psychiatric admission in 71.1% of cases. Both outcomes increased across OASS strata (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016, respectively). In multivariable analysis, severe agitation independently predicted psychiatric admission (adjusted OR 7.87, 95% CI 2.28\u201327.17), while increasing age was inversely associated (adjusted OR 0.91 per year, 95% CI 0.86\u20130.96). The optimism-corrected AUC for psychiatric admission was 0.76 (95% CI 0.66\u20130.85). In exploratory analysis, OASS\u2009\u2265\u20092 demonstrated a sensitivity of 81.8% and a negative likelihood ratio of 0.36.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Agitation severity was independently associated with psychiatric admission and showed a graded association with pharmacologic escalation in unadjusted analyses across OASS strata. Structured behavioral assessment using OASS may support early risk stratification and disposition planning in substance-related agitation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12873-026-01646-0","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:55:33Z","timestamp":1781744133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Agitation severity and emergency department outcomes in substance-related behavioral emergencies: a retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0053-5657","authenticated-orcid":false,"given":"Asli Bahar","family":"Ucar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4419-6135","authenticated-orcid":false,"given":"Nurseli","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5641-5112","authenticated-orcid":false,"given":"Gizem","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0946-3269","authenticated-orcid":false,"given":"Mustafa","family":"Aytemiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5448-188X","authenticated-orcid":false,"given":"Ezgi Hilal","family":"Ozan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-8251","authenticated-orcid":false,"given":"Arzu Denizbas\u0131","family":"Altinok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"1646_CR1","doi-asserted-by":"publisher","DOI":"10.18356\/9789211065534","volume-title":"World Drug Report 2024","author":"United Nations Office on Drugs and Crime (UNODC)","year":"2024","unstructured":"United Nations Office on Drugs and Crime (UNODC). World Drug Report 2024. Vienna: UNODC; 2024. https:\/\/www.unodc.org\/islamicrepublicofiran\/en\/unodc-world-drug-report-2024_-harms-of-world-drug-problem-continue-to-mount-amid-expansions-in-drug-use-and-markets.html. [accessed 28 January 2026]."},{"key":"1646_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13722-018-0117-1","volume":"13","author":"K Hawk","year":"2018","unstructured":"Hawk K, D\u2019Onofrio G. Emergency department screening and interventions for substance use disorders. Addict Sci Clin Pract. 2018;13:18. https:\/\/doi.org\/10.1186\/s13722-018-0117-1.","journal-title":"Addict Sci Clin Pract"},{"key":"1646_CR3","doi-asserted-by":"publisher","unstructured":"Pickens CM, Park J, Casillas SM, Liu S, Sheppard M, Stokes EK, Ko JY, Lee SH. Trends in Suspected Fentanyl-Involved Nonfatal Overdose Emergency Department Visits, by Age Group, Sex, and Race and Ethnicity \u2014 United States, October 2020\u2013March 2024. MMWR Morb Mortal Wkly Rep. 2025 May 8;74(16):282\u2013287. https:\/\/doi.org\/10.15585\/mmwr.mm7416a2","DOI":"10.15585\/mmwr.mm7416a2"},{"key":"1646_CR4","volume-title":"Turkey Drug Report 2024","author":"Republic of Turkey Ministry of Interior, Turkish National Police, Department of Anti-Narcotics","year":"2024","unstructured":"Republic of Turkey Ministry of Interior, Turkish National Police, Department of Anti-Narcotics. Turkey Drug Report 2024. Ankara: Turkish National Police; 2024. https:\/\/www.narkotik.pol.tr\/kurumlar\/narkotik.pol.tr\/Duyurular\/2024\/Eylul\/TURKISH_DRUG_REPORT.PDF. [accessed 29 January 2026]."},{"key":"1646_CR5","volume-title":"European Drug Report 2024: Trends and Developments","author":"EU Drugs Agency","year":"2024","unstructured":"EU Drugs Agency. European Drug Report 2024: Trends and Developments. Lisbon: EU Drugs Agency; 2024. https:\/\/www.euda.europa.eu\/publications\/european-drug-report\/2024_en. [accessed 28 January 2026]."},{"key":"1646_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.annemergmed.2017.01.036","volume":"69","author":"DJ Nazarian","year":"2017","unstructured":"American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on the Adult Psychiatric Patient, Nazarian DJ, Broder JS, Thiessen MEW, Wilson MP, Zun LS, et al. Clinical Policy: Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department. Ann Emerg Med. 2017;69:480\u201398. https:\/\/doi.org\/10.1016\/j.annemergmed.2017.01.036.","journal-title":"Ann Emerg Med"},{"key":"1646_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5811\/westjem.2011.9.6865","volume":"13","author":"GH Holloman Jr","year":"2012","unstructured":"Holloman GH Jr, Zeller SL. Overview of Project BETA: Best practices in Evaluation and Treatment of Agitation. West J Emerg Med. 2012;13:1\u20132. https:\/\/doi.org\/10.5811\/westjem.2011.9.6865.","journal-title":"West J Emerg Med"},{"key":"1646_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5811\/westjem.2011.9.6866","volume":"13","author":"MP Wilson","year":"2012","unstructured":"Wilson MP, Pepper D, Currier GW, Holloman GH Jr, Feifel D. The Psychopharmacology of Agitation: Consensus Statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. West J Emerg Med. 2012;13:26\u201334. https:\/\/doi.org\/10.5811\/westjem.2011.9.6866.","journal-title":"West J Emerg Med"},{"key":"1646_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","volume":"35","author":"DR Wesson","year":"2003","unstructured":"Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoact Drugs. 2003;35:253\u20139. https:\/\/doi.org\/10.1080\/02791072.2003.10400007.","journal-title":"J Psychoact Drugs"},{"key":"1646_CR10","doi-asserted-by":"publisher","unstructured":"Zun LS. Evidence-based review of pharmacotherapy for acute agitation. Part 1: Onset of Efficacy. J Emerg Med. 2018;54:364\u2009\u2013\u200974. https:\/\/doi.org\/10.1016\/j.jemermed.2017.10.011.","DOI":"10.1016\/j.jemermed.2017.10.011"},{"key":"1646_CR11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","volume":"84","author":"JT Sullivan","year":"1989","unstructured":"Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84:1353\u20137. https:\/\/doi.org\/10.1111\/j.1360-0443.1989.tb00737.x.","journal-title":"Br J Addict"},{"key":"1646_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1176\/jnp.9.4.541","volume":"9","author":"SC Yudofsky","year":"1997","unstructured":"Yudofsky SC, Kopecky HJ, Kunik M, Silver JM, Endicott J. The Overt Agitation Severity Scale for the objective rating of agitation. J Neuropsychiatry Clin Neurosci. 1997;9:541\u20138. https:\/\/doi.org\/10.1176\/jnp.9.4.541.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1646_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jemermed.2019.07.019","volume":"57","author":"AH Wong","year":"2019","unstructured":"Wong AH, Crispino L, Parker JB, McVaney C, Rosenberg A, Ray JM, et al. Characteristics and Severity of Agitation Associated With Use of Sedatives and Restraints in the Emergency Department. J Emerg Med. 2019;57:611\u20139. https:\/\/doi.org\/10.1016\/j.jemermed.2019.07.019.","journal-title":"J Emerg Med"},{"key":"1646_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.annemergmed.2018.04.027","volume":"72","author":"LR Klein","year":"2018","unstructured":"Klein LR, Driver BE, Miner JR, Martel ML, Hessel M, Collins JD, et al. Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department. Ann Emerg Med. 2018;72:374\u201385. https:\/\/doi.org\/10.1016\/j.annemergmed.2018.04.027.","journal-title":"Ann Emerg Med"},{"issue":"4","key":"1646_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.annemergmed.2018.06.001","volume":"72","author":"JR Miner","year":"2018","unstructured":"Miner JR, Klein LR, Cole JB, Driver BE, Moore JC, Ho JD. The Characteristics and Prevalence of Agitation in an Urban County Emergency Department. Ann Emerg Med. 2018;72(4):361\u201370. https:\/\/doi.org\/10.1016\/j.annemergmed.2018.06.001.","journal-title":"Ann Emerg Med"},{"issue":"2","key":"1646_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0022-3956(01)00052-8","volume":"36","author":"RH Swift","year":"2002","unstructured":"Swift RH, Harrigan EP, Cappelleri JC, Kramer D, Chandler LP. Validation of the Behavioral Activity Rating Scale (BARS): a novel measure of activity in agitated patients. J Psychiatr Res. 2002;36(2):87\u201395.","journal-title":"J Psychiatr Res"},{"key":"1646_CR17","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, Initiative STROBE. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X.","journal-title":"Lancet"},{"key":"1646_CR18","unstructured":"The jamovi project. jamovi. Version 2.4 [software]. Sydney: The jamovi project. 2023. [accessed 29 January 2026]. https:\/\/www.jamovi.org [accessed 29 January 2026]."},{"key":"1646_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.emc.2023.06.010","volume":"42","author":"C Wolfe","year":"2024","unstructured":"Wolfe C, McCoin N. Management of the Agitated Patient. Emerg Med Clin North Am. 2024;42:13\u201329. https:\/\/doi.org\/10.1016\/j.emc.2023.06.010.","journal-title":"Emerg Med Clin North Am"}],"container-title":["BMC Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12873-026-01646-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12873-026-01646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12873-026-01646-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:03:03Z","timestamp":1788800583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12873-026-01646-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1186\/s12873-026-01646-0","relation":{},"ISSN":["1471-227X"],"issn-type":[{"value":"1471-227X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by Marmara University Faculty of Medicine Clinical Research Ethics Committee (Approval No. 09.2025.25\u20130496) and conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective design and use of de-identified clinical data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"239"}}